Skip to content

Clinical study of ropivacaine with hydromorphone for brachial plexus block

Clinical study of ropivacaine with hydromorphone for brachial plexus block

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008654
Enrollment
Unknown
Registered
2016-06-15
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical study of ropivacaine with hydromorphone for brachial plexus block

Interventions

Group L:Simple injection of 0.5% ropivacaine 25ml
Group Q1:Injection hydromorphone 0.25mg with 0.5% ropivacaine 25ml
Group Q2:Injection hydromorphone 0.25mg with 0.5% ropivacaine 25ml
Group Q3:Injection hydromorphone 0.75mg with 0.5% ropivacaine 25ml

Sponsors

The Second Affiliated Hospital of Wenzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 100 patients with American Society of Anesthesiologists (ASA) physical status I/II who were scheduled for upper extremity surgery under brachial plexus block was to be used were enrolled in this prospective, doubleblind, controlled trial.

Exclusion criteria

Exclusion criteria: (1) to test suspected drug allergy; (2) in patients weighing more than 100kg; (3) preoperative New York Heart Association (NYHA) class III or IV persons; (4) Consolidated heart, liver, kidney, hematopoietic system and other vital organs and systems of serious primary disease or ALT, more than 2 times of the upper limit of normal AST level, Cr exceeds the upper limit of normal level; (5) preoperative hemoglobin 160g/L, or hematocrit <30% significantly; preoperative platelet count <=100* 10^9/L persons; preoperative coagulation prompt PT or APTT greater than the upper limit of normal by 1.5 times; (6) Liquid overload, including pulmonary edema; (7) serum K+, Na+, Mg2+, Cl- abnormalities; (8) with severe systemic infection; (9) associated with neurological and psychiatric disorders while not cooperate or unwilling collaborators; (10) during pregnancy, lactation or recent fertility planner; (11) within the past three months those who participated in other clinical trials; (12) The researchers consider it appropriate to participate in the clinical trial were.

Design outcomes

Primary

MeasureTime frame
Radial nerve, ulnar nerve, median nerve pain perception (acupuncture) and exercise (shoulder. Elbow, wrist) disappearance time;Radial nerve, ulnar nerve, median nerve pain feel upper limb motor recovery time;Monitor blood pressure and breathing;

Countries

China

Contacts

Public ContactZhang Xuehua

The Second Affiliated Hospital of Wenzhou Medical College

zxhmn0126@sina.com+86 13587662708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026